Vincristine sulfate

For research use only.

Catalog No.S1241 Synonyms: Leurocristine

51 publications

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate (Leurocristine) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 88 In stock
EUR 68 In stock
EUR 265 In stock
EUR 855 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Vincristine sulfate has been cited by 51 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Vincristine sulfate (Leurocristine) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 MojLR4VtdCCYaXHibYxqfHliQYPzZZk> MWqwMVAvPSEQvF2= NFTOOIszPCCq NWnHUWI6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= MXOyOVY3Ozd4OR?=
HepG2-HBV1.1 M{H0WWFxd3C2b4Ppd{BCe3OjeR?= M4TkRlAuOC53IN88US=> NGTheIMzPCCq M3H1fIlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= Mn7pNlU3PjN5Nkm=
HepG2.2.15 NUjtTWFXTnWwY4Tpc44hSXO|YYm= NXnqXpplOC5zIN88US=> M1;6Z|I1KGh? MoXidJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u NWXjWJBsOjV4NkO3Olk>
HepG2-HBV1.1 MlLXSpVv[3Srb36gRZN{[Xl? NHPZcJMxNjFizszN NWqxS2VjOjRiaB?= M1TPZZBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> M37QO|I2PjZ|N{[5
HepG2-HBV1.1 MojESpVv[3Srb36gRZN{[Xl? NXLJXmU6OC5zIN88US=> NXPoXJJrPDhiaB?= NWHpO2hReHKxbX;0[ZMh[2WubDDlfINz\XSrb36gc4YhcGWyYYTpeIl{KEJidnnyeZMhdnWlbHXvZ4Fxe2mmczDpcpN1\WGmIH;mJIhmeGG2aYTpd{BDKH[rcoXzJGRidmVicHHyeIlkdGW| M1LucFI2PjZ|N{[5
HepG2-HBV1.1 NIn4N2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:wMlEh|ryP NV\mWnIzOS13IHS= NUTBNJprcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=> NGX5S3kzPTZ4M{e2PS=>
HepG2-HBV1.1 M1\1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon4NE4yKM7:TR?= MknnNU02KGR? NETuXZZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 MYmyOVY3Ozd4OR?=
HepG2-HBV1.1 NHfM[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfTdFYxNjFizszN M3PFR|EzNTd{IHi= NELmPZdqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> MnXENlU3PjN5Nkm=
HepG2-HBV1.1 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH3Zog2OC5zIN88US=> MlS4NVIuPzJiaB?= M33Geolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> MlKzNlU3PjN5Nkm=
Raji NX3j[Jp2TnWwY4Tpc44hSXO|YYm= M3j6N|AvPcLizszN NHjzSYo4OiCq NVPrTmNX[WKxbHnzbIV{KGG3dH;wbIFogcLi NIrhRoIzPTR2NkO3Oy=>
SK-MEL-28  NHjnSlZHfW6ldHnvckBCe3OjeR?= M2P6U|MxKG6P NHrCR483KGh? M4T3b4lv\HWlZYOgS|LjiJOPIHPlcIwu[3mlbHWgZZJz\XO2 NH7PSlMzPTNzM{CxNC=>
H157 NGP2PXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe2WYltUUN3ME2xMlA{KMLzIECuNFQhdWm3Ml2= MmX6NlUzPTd7MUG=
Jurkat NE[0SW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexMVMhdk1? NYeyXVBUPDkEoHi= NWj3PZU5TE2VTx?= M4XvSYRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> MXuyOVE2PjF2Nh?=
CEM MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37DS|EuOyCwTR?= MX:0POKhcA>? MYjEUXNQ NVLtd5JO\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NITHT2gzPTF3NkG0Oi=>
P12 NH;idINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnlU2wyNTNibl2= NFrNXoE1QMLiaB?= M4rx[2ROW09? MlrT[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> MYeyOVE2PjF2Nh?=
KB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULsfpdoUUN3ME2wMlAxPDliwsGgNE4xODBzIN88US=> NGnwfWgzPTB3OEWyOi=>
KBv200 (ABCB1) M1[4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PUO2lEPTB;MD6zOFYzKMLzIECuNFA3PiEQvF2= MlnYNlUxPTh3Mk[=
SUDHL6  NEPuUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;INgKBkc7:TR?= NHvnbXU1QC95MjDo NHHTbphqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NHjCbVgzPDl4MU[wOC=>
SUDHL6  NWLZV|V2TnWwY4Tpc44hSXO|YYm= MV:x5qCK|ryP M{e4ZlczKGh? NVXENlRWcW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI91cWNibX;ydIhwdG:peTDjbIFv\2W|IHPveJJme3SnZDD3bZRpKEKFTEGxRUB{cVKQQR?= M{ftZVI1QTZzNkC0
HCT-116 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonmS2k2OD13IH7N M4LDXFI1QTJ5OEW3
SKNBe2C NF;G[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPyTWM2OD1|Mj64xtE1NjBibl2= NVvOXItSOjR7MkG5NlA>
IGNR91 NIrFOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCzTWM2OD1{ND6zxtEyNjdibl2= MV:yOFkzOTl{MB?=
SKNAS MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\td4JKSzVyPUGuOeKyOC5{IH7N MkjKNlQ6OjF7MkC=
LAN1 NY\LWFlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XIWmlEPTB;Mj6zxtExNjJibl2= MY[yOFkzOTl{MB?=
SHSY5Y NGDufXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17zXGlEPTB;OD6yxtExNjZibl2= M4DZblI1QTJzOUKw
A549-WT NXHLWXo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF7LkSzO{DDuSByLkW5OEAhdk1? NWXVfWY5OjR6NUi4Nlc>
A549-R MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1? MVKyOFg2QDh{Nx?=
MCF-7-WT NIe3TFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq5TWM2OD1zNz63OVIhyrFiMD6yNVghKG6P Mm\0NlQ5PTh6Mke=
MCF-7-R MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH0TWM2OD13LkWzPUDDuSByLkG0OEAhdk1? MYWyOFg2QDh{Nx?=
A549-R NVTUOo53S3m2b4TvfIlkcXS7IFHzd4F6 MYPJR|UxRTF{LkG3PEDDuSByLkOzN{BvVQ>? NIfUXVkzPDh3OEiyOy=>
MCF-7-R NWDMVGJ6S3m2b4TvfIlkcXS7IFHzd4F6 NHPjfHlKSzVyPUWuOVM6KMLzIECuNVQ1KG6P NYqzS4htOjR6NUi4Nlc>
SW620 NVT5enVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqy[mZIUUN3ME23MlgxKMLzIECuNFghdk1? NVPGRoFEOjR5Mk[3N|k>
SW620/AD300 NEDNV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTlyOT62NEDDuSB6LkmxJI5O M{DwN|I1PzJ4N{O5
HEK293/pcDNA3.1 Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P1VmlEPTB;MT60OUDDuSByLkKwJI5O MlzvNlQ4OjZ5M{m=
HEK293/ABCC1 NHjNUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq5TWM2OD1zOT6yPUDDuSB{LkC4JI5O M{G4WVI1PzJ4N{O5
TCC M3jEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DKSlI1KGh? NFf1PGFKSzVyPUewJI5O M2PmNFI1PzF4OUS0
TCC MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[3SYs1QCCq NYrjTXBzUUN3ME21NEBvVQ>? MnfONlQ4OTZ7NES=
HepG2/ADM M1fnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILRNXRKSzVyPUKuO|g3O8LzMD6yN|cyKM7:TR?= NWTtO25qOjR5MES1OVY>
HepG2 NWnu[pNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMEGxOeKyOC5yMEG3JO69VQ>? MV[yOFcxPDV3Nh?=
MCF-7/ADR NGn2[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHFTlFoUUN3ME20MlQ5OjcEsUCuNlA4OCEQvF2= Mlf3NlQ4ODR3NU[=
MCF-7 NITjSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXURZFMUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= MXqyOFcxPDV3Nh?=
A-172  NV[5[4VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfZWVAxNjIEoN88US=> M{f4d|I1Nzd{IHi= NYXjTW9CcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? M2fhfFI1PTNyMkO1
U-251MG M17wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\VUpNsOC5zwrFOwG0> M4LoV|I1Nzd{IHi= MY\pcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 M2\hWFI1PTNyMkO1
DLD-1 MnjGSpVv[3Srb36gRZN{[Xl? M{CxRlExOCCwTR?= NYHJc3N3PDhiaB?= M1f6UpBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? MlrhNlQ1ODN2NUO=
CCD18Co NW\zXYxOTnWwY4Tpc44hSXO|YYm= NV;Ed4d6OTByIH7N NHPVXJA1QCCq NGmyPWRxem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB? MoX2NlQ1ODN2NUO=
DLD-1 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3XTlUxNTFyMECgcm0> NHnEU|E1QCCq MkLGbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NFrk[2MzPDRyM{S1Ny=>
CCD18Co NWLKSphnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXBVFhJOC1zMECwJI5O M1fhSFQ5KGh? NID2ZlNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M3Hn[lI1PDB|NEWz
HepG2 NWXpWpZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXMNlQhcA>? MkftTWM2OD13Mj615qCK|ryP MWSyOFM1OTZ6OB?=
HEK293/pcDNA3.1 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LtNWlEPTB;MD6wNFTDuTBwMECwN{DPxE1? Mn7hNlQzQDR5OEO=
HEK293/MRP1 NITuOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnqcYxKSzVyPUCuNFU2yrFyLkCxNlAh|ryP NHnO[nQzPDJ6NEe4Ny=>
Ramos NUDMUpVHSXCxcITvd4l{KEG|c3H5 NHnYTYYz6oDLzszN MXG0PEBp NVLFe2JRcW6mdXPld{A{PC54JdMxNU46OiViYYDvdJRwe2m| MYWyOFI2PjR7MR?=
NCI-H1299/pcDNA3 NH\ndJdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2DnOFAuOjBibl2= NFPGeZQ6PiCq NUHzb|VWcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NFewfmszPDF5N{CxNi=>
H1299/ICAM-3 M{Do[mNmdGxiVnnhZoltcXS7IFHzd4F6 NFnyR2IxNTJyIH7N NYDq[plxQTZiaB?= M1XVSYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MU[yOFE4PzBzMh?=
NCI-H1299/pcDNA3 M2C1[WZ2dmO2aX;uJGF{e2G7 NHO3dIEyNzVxMUCvNlDDqG6P NVnITXpHQTZiaB?= NIfoN3NqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR MYSyOFE4PzBzMh?=
H1299/ICAM-3 M1TmNmZ2dmO2aX;uJGF{e2G7 NXex[|U6OS93L{GwM|IxyqCwTR?= MWS5OkBp NY[yeJc4cW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? M4HqdlI1OTd5MEGy
W1 NGTTU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMECzNkDPxE1? M1uzcVI1OTRyMUe2
W1VR NEfINlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEW2JO69VQ>? NEfpRokzPDF2MEG3Oi=>
K562 M1LwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Xq[WlEPTB;MD6wN|IhyrFiMD6wNFEhKM7:TR?= NXznZ5VMOjRzM{W5N|c>
K562/ADR MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLpcFlWUUN3ME2zMlI3OSEEsTCwMlQyOiEQvF2= MlPpNlQyOzV7M{e=
K562 NV7pN5g4SXCxcITvd4l{KEG|c3H5 MnHqNE4{KM7:TR?= NYPZOpA2OjRiaB?= M4mwTolv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? M33x[FI1OTN3OUO3
K562/ADR M{fZU2Fxd3C2b4Ppd{BCe3OjeR?= NFy5doU{KM7:TR?= M3KxVVI1KGh? M4XrXYlv\HWlZYOgZZBweHSxc3nz M{nEblI1OTN3OUO3
A549 M37FOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHYO49qUUN3ME2wMlExKMLzIECuNFMh|ryP NGjuSHEzOzl5MUC3OS=>
K562 NYGwT|RmS2WubDDWbYFjcWyrdImgRZN{[Xl? MnLYN{44PeLCk{[wxsBvVQ>? MVq3NuKhcMLi Ml7FbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MXeyN|g4PzJ{Mx?=
lucena MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4jtPFMvPzYkgKO2NOKhdk1? NHzvdG44OsLiaNMg M3rvNY5wKGWoZnXjeC=> MV:yN|g4PzJ{Mx?=
FEPS NGHNXHdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mke3N{44PeLCk{[wxsBvVQ>? NILVfYE4OsLiaNMg Mlj2co8h\W[oZXP0 MkHWNlM5Pzd{MkO=
A2780 NHG2b2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNwNTDtUS=> NVv2NZVGOjN6MkmyNFM>
ACHN NWfDV5A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7ZfmlKSzVyPECuNUBuVQ>? M4jIT|I{QDJ7MkCz
U-937 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfOUGFKSzVyPEO0JI5O MYSyN|gzQTJyMx?=
Jurkat MkLjRZBweHSxc3nzJGF{e2G7 MXi1xsDPxGdxbX|CpC=> M2TkXVI1KGh? NF3VNWJqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 MnzkNlM5OTB2MEm=
Jurkat NX\w[FN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLyTZA2PcLizsznM41tyqB? NXfVVY5KOjRiaB?= NUHNOmtt[XK{ZYP0JGp2emujdDDj[YxteyCrbjDHNk9OKHCqYYPl MlXmNlM5OTB2MEm=
Hep-2 NFOxSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEVCtVAvODFizszN MonWNlM4QDB2MkS=
Hep-2/v MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nLTGlEPTB;MT64xtExNjJyIN88US=> NYHZT2VZOjN5OEC0NlQ>
SGC-7901 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fLPFAuOTBizsznM41t MXKyOE81QC95MjDo MnLHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MoCwNlM4PDN3N{K=
SGC-7901/VCR NIradmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\VbZRbOC1zMDFOwIcwdWx? M2CwNFI1NzR6L{eyJIg> MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M4nBfVI{PzR|NUey
SGC-7901 NWfXUYdNSXCxcITvd4l{KEG|c3H5 NF3mOJhqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NVf1RmN3OjN5NEO1O|I>
SGC-7901/VCR MmHzRZBweHSxc3nzJGF{e2G7 Ml7UbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? M1\Y[FI{PzR|NUey
KB-3-1 MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvLV4dKSzVyPUGuOlYhyrFiMD6xOlIh|ryP MW[yN|Y4OzR2NR?=
KB-C2 M1zFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TXcGlEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2= NXz5dXpsOjN4N{O0OFU>
KB-3-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTWclRqUUN3ME2xMlI3KMLzIECuNFI4KM7:TR?= M3P2dlI{Pjd|NES1
KB-V1 NIKwR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqwOlRKSzVyPUKwPE45PSEEsTCyNE41KM7:TR?= MUmyN|Y4OzR2NR?=
HEK293/pcDNA3.1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ2LkGgxtEhOC5{MESg{txO MmPrNlM3PzN2NEW=
HEK293/ABCB1 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULRZo5CUUN3ME2zOVEzNjhiwsGgN|c5NjN7MTFOwG0> MlviNlM3PzN2NEW=
A549/EGFP  Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC5NE4xOS1zMECwJO69VQ>? NULw[Gh6UUN3ME24Ok44KMLzIEK5MlEh|ryP M3Lz[FI{PjN2Mkiy
A549/Slug NVjUZ45pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOwMlAyNTFyMECg{txO MnXzTWM2OD17LkegxtEhOy5zIN88US=> M4P6bVI{PjN2Mkiy
JFCR39  MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3sd3hYOSEEtV2= MViyOEBp NXHXXmdWTE2VTx?= M3zSbo1iemunZHz5JIlv[3KnYYPld{B1cGViboXtZoVzKG:oIFeyM20heGijc3WgZ4VtdHN? NIT4c48zOzV7OEK3Oi=>
A549 Mlu4SpVv[3Srb36gRZN{[Xl? MnWxNVAxKG6P MWOxOkBp NGX5TmZFVVOR NH7nUmNt\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW| MlfCNlM2QTh{N{[=
SGC7901 NIjBe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXMc3hKSzVyPUGuNlbjiIoEsfMAjVAvOTFizsznM41t MXyyN|U3PDR6Mh?=
SGC7901/LV-NC NUftVXZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3KfIdPUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>? M{LhPFI{PTZ2NEiy
SGC7901/LV-SGO1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTRwM{dihKnDueLCiUCuN|ch|rypL33s NETXfY0zOzV4NES4Ni=>
SGC7901/VCR NH;3bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2mwSWlEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t M{frdlI{PTZ2NEiy
SGC7901/VCR-NC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nCWWlEPTB;MUmuPFbjiIoEsfMAjVIvODFizsznM41t Mn7oNlM2PjR2OEK=
SGC7901/VCR-si-SGO1 NVvZbVhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvYTWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=> MoXtNlM2PjR2OEK=
SGC7901/ADR NWXrOpk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfC[JVKSzVyPUeuPFXjiIoEsfMAjVAvPjRizsznM41t NGn6OWQzOzV4NES4Ni=>
SGC7901/ADR-NC NH7GeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qzcGlEPTB;OD65N-KBkcLz4pEJNE43QCEQvHevcYw> MVSyN|U3PDR6Mh?=
SGC7901/ADR-si-SGO1 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HBN2lEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw> MlrMNlM2PjR2OEK=
SH-SY5Y  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrSNE4xODFvMUCg{txO MWeyOEBp MojWTWM2OD1yLkGxN:KyOC5yMUKg{txO M2XFcFI{OTJ7ME[1
SH-SY5Y  M{fpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL5dVQ{OC5yMEGtNVAh|ryP MXO0PEBp M1O0bGlEPTB;MD6wO|jDuTBwMEC5JO69VQ>? MYeyN|EzQTB4NR?=
SH-SY5Y  NIribXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[wMlAxOS1zMDFOwG0> Ml\FO|IhcA>? MYnJR|UxRTBwMEWxxtExNjByODFOwG0> M3vJfFI{OTJ7ME[1
SH-SY5Y NWexdpdVSXCxcITvd4l{KEG|c3H5 Mn\PNE4yKM7:TR?= M{PiNVAuOjRiaB?= NY\MeWR2cW6mdXPld{BieG:ydH;zbZMhd2ZiU1itV3k2YSClZXzsd{Bnd2yub4fpcoch[2WubDDjfYNt\SCjcoLld5Qh[XRidHjlJGczN01icHjhd4U> NYrMW2NbOjNzMkmwOlU>
SH-SY5Y NYXqcXR1SXCxcITvd4l{KEG|c3H5 NV\FblVLOC5zIN88US=> NGHj[3UxNTJ2IHi= M2OzSolv\HWlZYOgcYl1d3SrYzDhdpJme3UEoB?= NUjLfIZ7OjNzMkmwOlU>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; 

PubMed: 26156322     


MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine

26156322
Growth inhibition assay
Cell viability ; 

PubMed: 26156322     


MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively.  Cell viability was measured by MTT assay.

26156322
In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine
Smiles CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04448834 Not yet recruiting Drug: Blinatumomab B-cell Acute Lymphoblastic Leukemia David Rizzieri MD|Amgen|Acrotech Biopharma|Duke University September 1 2020 Phase 2
NCT03981510 Recruiting Diagnostic Test: 3D-Transit Constipation|Childhood Acute Lymphoblastic Leukemia|Neurofibromatosis 1|Chronic Constipation With Overflow University of Aarhus June 2019 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID